Valiant Laboratories Ltd. (IN:VALIANTLAB)
:VALIANTLAB
Want to see IN:VALIANTLAB full AI Analyst Report?
Top Page
Valiant Laboratories Ltd.
(VALIANTLAB)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹70.00
▼(-4.76% Downside)
Action:Reiterated
Date:05/18/26
The score is held back primarily by weak financial quality—losses, near break-even operating profitability, and negative operating/free cash flow—despite a healthier balance sheet and a notable FY2026 revenue rebound. Technicals are supportive with the stock trading above key moving averages and positive MACD momentum, but valuation remains constrained because the company is currently unprofitable and offers no dividend yield data.
Positive Factors
Relatively strong balance sheet / modest leverage
Equity far exceeds debt (approx. 3.11B vs 0.46B), implying limited financial leverage and greater resilience to shocks. This provides durable financial flexibility to fund working capital, capex or strategic initiatives without immediate refinancing pressure over the next several months.
Negative Factors
Profitability deterioration to losses
Two consecutive years of losses and only near-break-even operating profit reduce internal reinvestment capacity and raise questions about core operating efficiency. Persistent unprofitability undermines long-term margin sustainability and limits ability to finance growth organically.
Read all positive and negative factors
Positive Factors
Negative Factors
Relatively strong balance sheet / modest leverage
Equity far exceeds debt (approx. 3.11B vs 0.46B), implying limited financial leverage and greater resilience to shocks. This provides durable financial flexibility to fund working capital, capex or strategic initiatives without immediate refinancing pressure over the next several months.
Read all positive factors
Valiant Laboratories Ltd. (VALIANTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.75B
Dividend YieldN/A
Average Volume (3M)1.58K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue Growth78.04%
EPS Growth-16.99%
CountryIN
Employees77
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.13
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valiant Laboratories Ltd. Business Overview & Revenue Model
Company Description
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in va...
How the Company Makes Money
The company makes money mainly by manufacturing and selling APIs/bulk drugs to customers in the pharmaceutical industry. Revenue is generated from (1) sales of APIs to domestic and/or international pharma companies that use these ingredients to pr...
Valiant Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
71
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.84B | 2.37B | 1.39B | 1.82B | 3.34B | 2.92B |
| Gross Profit | 267.32M | 272.66M | 222.17M | 115.76M | 565.90M | 523.21M |
| EBITDA | 92.87M | 63.90M | 7.55M | -85.98M | 399.53M | 442.67M |
| Net Income | 50.70M | -32.68M | -22.01M | 3.20M | 289.98M | 274.96M |
Balance Sheet | ||||||
| Total Assets | 4.25B | 4.64B | 4.01B | 3.43B | 2.13B | 1.82B |
| Cash, Cash Equivalents and Short-Term Investments | 629.06M | 331.50M | 759.91M | 1.44B | 353.61M | 205.33M |
| Total Debt | 537.68M | 462.12M | 1.22B | 767.08M | 602.17M | 611.26M |
| Total Liabilities | 1.07B | 1.53B | 1.67B | 1.06B | 1.12B | 1.10B |
| Stockholders Equity | 3.17B | 3.11B | 2.34B | 2.37B | 1.00B | 714.60M |
Cash Flow | ||||||
| Free Cash Flow | -1.39B | -471.97M | -1.13B | -439.85M | 183.70M | -46.25M |
| Operating Cash Flow | -57.24M | -129.97M | 13.13M | 18.85M | 560.51M | 22.51M |
| Investing Cash Flow | -604.96M | 72.52M | -527.68M | -1.44B | -551.68M | -122.38M |
| Financing Cash Flow | 576.22M | 43.57M | 446.53M | 1.52B | -9.34M | 61.81M |
Valiant Laboratories Ltd. Technical Analysis
Negative
73.50
Price Trends
73.19
Negative
65.50
Positive
71.60
Negative
Market Momentum
-1.90
Positive
40.85
Neutral
31.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VALIANTLAB, the sentiment is Negative. The current price of 73.5 is above the 20-day moving average (MA) of 73.21, above the 50-day MA of 73.19, and above the 200-day MA of 71.60, indicating a bearish trend. The MACD of -1.90 indicates Positive momentum. The RSI at 40.85 is Neutral, neither overbought nor oversold. The STOCH value of 31.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VALIANTLAB.
Valiant Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | ₹3.56B | 27.09 | ― | ― | 36.73% | 30.29% | |
60 Neutral | ₹6.10B | 96.06 | ― | ― | -1.22% | -52.32% | |
56 Neutral | ₹3.70B | 32.96 | ― | ― | 3.26% | 167.18% | |
55 Neutral | ₹4.05B | -271.81 | ― | 0.66% | -3.52% | -108.70% | |
55 Neutral | ₹3.04B | 24.44 | ― | 0.26% | 21.67% | 23.11% | |
54 Neutral | ₹3.75B | -115.29 | ― | ― | 78.04% | -16.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:VALIANTLAB
Valiant Laboratories Ltd.
67.90
-35.82
-34.54%
IN:ALBERTDAVD
Albert David Ltd
715.15
-119.97
-14.37%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
163.35
89.34
120.71%
IN:MEDICAMEQ
Medicamen Biotech Limited
227.65
-168.61
-42.55%
IN:MEDICO
Medico Remedies Ltd.
42.58
-6.61
-13.44%
IN:ZIMLAB
Zim Laboratories Ltd.
119.45
9.07
8.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.